

Recombinant SLC7A5/LAT1 Monoclonal Antibody

catalog number: AN301897L

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description



Reactivity	Human;Mouse;Rat
Immunogen	Recombinant human SLC7A5/LAT1 fragment
Host	Rabbit
Isotype	Rabbit IgG
Clone	C121518
Purification	Protein A purified
Buffer	PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant.

Applications

Recommended Dilution

WB	1:2000-1:10000
IHC	1:200-1:1000

Data




Western Blot with SLC7A5/LAT1 Monoclonal Antibody at dilution of 1:10000. Lane 1: HT-1080, Lane 2: HepG2, Lane 3: K562

Immunohistochemistry of paraffin-embedded Human lung squamous cell carcinoma using SLC7A5/LAT1 Monoclonal Antibody at dilution of 1:1000.

Observed-MW:39 kDa

Calculated-MW:55 kDa



Immunohistochemistry of paraffin-embedded Human testis using SLC7A5/LAT1 Monoclonal Antibody at dilution of 1:1000.

Preparation & Storage

Storage	Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
Shipping	Ice bag

Background

For Research Use Only

Toll-free: 1-888-852-8623
Web: www.elabscience.com

Tel: 1-832-243-6086
Email: techsupport@elabscience.com

Fax: 1-832-243-6017

Rev. V1.3

L-type amino acid transporter 1 (LAT1), also known as Solute carrier family 7 member 5 (SLC7A5), is a high-affinity neutral transporter of larger amino acids. It facilitates the cellular amino acid uptake in a sodium independent manner and selectively transports D-and L-isomers of small neutral amino acids. LAT1 also regulates amino acid exchange in conjunction with solute carrier family 1 member 5 (SLC1A5). Transport of thyroid hormones across the placenta is established via LAT1 during normal fetal development. LAT1 promotes neuronal cell proliferation by regulating the transport of amino acids across the blood brain barrier. LAT1 is upregulated in various cancer types including breast cancer, lung cancer, prostate cancer, and gliomas. High expression of LAT1 is detected in non-small cell lung cancer with lymph node metastases. Increased LAT1 expression is a novel biomarker of high-grade malignancy in prostate cancers. Inhibition of LAT1 suppresses tumor cell growth in several tumor types.